Search

Your search keyword '"Zhu, Guang-Zhi"' showing total 36 results
Start Over Author "Zhu, Guang-Zhi" Search Limiters Peer Reviewed Publication Year Range Last 10 years
36 results on '"Zhu, Guang-Zhi"'

7. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy

Author

Wei, Yong-Guang, primary, Su, Hao, additional, Lv, Zi-li, additional, Liao, Xi-Wen, additional, Zeng, Zhi-Ming, additional, Jia, Yu-Xuan, additional, Huang, Hua-Sheng, additional, Shen, Xiao-Qiang, additional, Zhu, Guang-Zhi, additional, Han, Chuang-Ye, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2023
Full Text
View/download PDF

10. Characterization of hepatocarcinogenesis by transcriptome and exome sequencing via chronic HBV X expression and aflatoxin B1 exposure in immortal hepatic cell

Author

Wang, Xiang-Kun, primary, Zhou, Xin, additional, Yu, Ting-Dong, additional, Han, Chuang-Ye, additional, Zhu, Guang-Zhi, additional, Qin, Wei, additional, Huang, Jian-Lu, additional, Liao, Xi-Wen, additional, Chen, Zi-Jun, additional, Yang, Cheng-Kun, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2022
Full Text
View/download PDF

16. Oncogene UBE2I enhances cellular invasion, migration and proliferation abilities via autophagy-related pathway resulting in poor prognosis in hepatocellular carcinoma

Author

Wang, Xiang-Kun, Liao, Xi-Wen, Zhou, Xin, Han, Chuang-Ye, Chen, Zi-Jun, Yang, Cheng-Kun, Huang, Jian-Lu, Wang, Jian-Yao, Liu, Jun-Qi, Huang, Hua-Sheng, Mo, Shu-Tian, Ye, Xin-Ping, Zhu, Guang-Zhi, and Peng, Tao

Subjects
Original Article, digestive system diseases
Abstract

Hepatocellular carcinoma (HCC) is a worldwide malignancy with high morbidity and mortality. In this study, ubiquitin conjugating enzyme E2I (UBE2I), a small ubiquitin-like modifier E2 enzyme reportedly expressed in tumors, was examined for its potential effects in HCC. Bioinformatics analysis was performed based on HCCDB, TIMER, and Kaplan-Meier plotter databases to explore the clinical implications in HCC. An siRNA kit was used to downregulate UBE2I, and in vitro experiments-including migration, invasion and proliferation assays-were performed to examine UBE2I expression in HCC. Western blot (WB) was used to determine whether downregulated UBE2I expression influenced the prognosis of HCC via autophagy pathways. Finally, RNA-sequencing was performed to explore candidate molecular mechanisms underlying the effect of UBE2I. Bioinformatics analysis including stratification by alcohol ingestion and hepatitis status in HCC showed that highly expressed UBE2I was not only correlated with poor prognosis, but was also associated with immune infiltrates. In vitro experiments showed that high expression of UBE2I was associated with increased migration, invasion and proliferation of HCC cells. WB results indicated that downregulated expression of UBE2I was associated with higher levels of autophagy-related proteins including LC3A/B, Beclin-1 and ATG16L1. Moreover, RNA-sequencing results suggested that UBE2I was involved in hepatocarcinogenesis, non-alcohol fatty liver disease, steatohepatitis, liver fibrosis, inflammation, hepatoblastoma, tumor angiogenesis, type 2 mellitus diabetes, biliary tract disease and other diseases. We conclude that oncogene UBE2I is associated with poor prognosis of HCC via autophagy pathways and may be involved in hepatocarcinogenesis, tumor angiogenesis, non-alcohol fatty liver disease and inflammation.

Published
2020

17. The Perspective of Diagnostic and Prognostic Values of Lipoxygenases mRNA Expression in Colon Adenocarcinoma

Author

Ruan,Guo-Tian, Gong,Yi-Zhen, Zhu,Li-Chen, Gao,Feng, Liao,Xi-Wen, Wang,Xiang-Kun, Zhu,Guang-Zhi, Liao,Cun, Wang,Shuai, Yan,Ling, Xie,Hai-Lun, Zhou,Xin, Liu,Jun-Qi, Shao,Meng-Nan, and Gan,Jia-Liang

Subjects
OncoTargets and Therapy
Abstract

Guo-Tian Ruan1 ,* Yi-Zhen Gong1 ,* Li-Chen Zhu,2 Feng Gao,1 Xi-Wen Liao,3 Xiang-Kun Wang,3 Guang-Zhi Zhu,3 Cun Liao,1 Shuai Wang,1 Ling Yan,1 Hai-Lun Xie,1 Xin Zhou,3 Jun-Qi Liu,3 Meng-Nan Shao,4 Jia-Liang Gan1 1Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China; 2Department of Immunology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China; 3Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China; 4Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jia-Liang GanDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of ChinaEmail gjl5172@163.comBackground: This study was mainly to explore and study the potential application of lipoxygenases (ALOX) family genes in the diagnostic and prognostic values of colon adenocarcinoma (COAD).Methods: Data sets related to the ALOX genes of COAD were obtained from The Cancer Genome Atlas and the University of California, Santa Cruz Xena browser. Then, the relevant biological information was downloaded from the public data platform. Finally, the bioinformatics technologies and clinical verification were employed to comprehensively analyze the potential values of ALOX genes.Results: The Pearson correlation analysis indicated that there were correlations among ALOXE3, ALOX5, ALOX12, and ALOX12B. The diagnostic receiver operating characteristic (ROC) curves suggested that ALOXE3 and ALOX12 had significant diagnosis in COAD: ALOXE3; P< 0.001, area under curve (AUC) 95%CI:=0.818 (0.773– 0.862) and ALOX12; P< 0.001, AUC 95%CI=0.774 (0.682– 0.807). Besides, the verification study indicated that ALOX12 had a diagnostic value in COAD. Finally, our multivariate survival analysis and comprehensive prognosis of ALOX genes in COAD suggested that the ALOXE3 and ALOX12 were associated with COAD overall survival: ALOXE3; P=0.025, HR 95%CI=1.765 (1.074– 2.901), ALOX12; P=0.046, HR 95%CI=1.680 (1.009– 2.796), and the low expression of ALOXE3 and ALOX12 had a favorable prognosis of COAD (all P< 0.05); on the contrary, the high regulation of them increased the risk of death.Conclusion: In our study, we observed that the mRNA expressions of ALOX genes were associated with the diagnosis and prognosis of COAD. The results of the diagnostic analysis suggested that ALOX12 might have a diagnosis value in COAD. Besides, our comprehensive prognosis analysis indicated that ALOXE3 combined ALOX12 might serve as potential prognosis biomarkers for COAD.Keywords: mRNA, colon adenocarcinoma, diagnostic, prognostic, The Cancer Genome Atlas, lipoxygenases

Published
2020

18. Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort

Author

Gong, Yi-Zhen, primary, Ma, Hui, additional, Ruan, Guo-Tian, additional, Zhu, Li-Chen, additional, Liao, Xi-Wen, additional, Wang, Shuai, additional, Yan, Ling, additional, Huang, Wei, additional, Huang, Ke-Tuan, additional, Xie, Hailun, additional, Zhu, Guang-Zhi, additional, Wang, Xiang-Kun, additional, Liao, Cun, additional, and Gao, Feng, additional

Published
2021
Full Text
View/download PDF

19. SOX4 as biomarker in hepatitis B virus-associated hepatocellular carcinoma

Author

Huang, Jian-Lv, primary, Wang, Xiang-Kun, additional, Liao, Xi-Wen, additional, Han, Chuang-Ye, additional, Yu, Ting-Dong, additional, Huang, Ke-Tuan, additional, Yang, Cheng-Kun, additional, Liu, Xiao-Guang, additional, Yu, Long, additional, Zhu, Guang-Zhi, additional, Su, Hao, additional, Qin, Wei, additional, Han, Quan-Fa, additional, Liu, Zheng-Qian, additional, Zhou, Xin, additional, Liu, Jun-Qi, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2021
Full Text
View/download PDF

20. Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Author

Liu, Jun-qi, primary, Liao, Xi-wen, additional, Wang, Xiang-kun, additional, Yang, Cheng-kun, additional, Zhou, Xin, additional, Liu, Zheng-qian, additional, Han, Quan-fa, additional, Fu, Tian-hao, additional, Zhu, Guang-zhi, additional, Han, Chuang-ye, additional, Su, Hao, additional, Huang, Jian-lu, additional, Ruan, Guo-tian, additional, Yan, Ling, additional, Ye, Xin-ping, additional, and Peng, Tao, additional

Published
2020
Full Text
View/download PDF

21. Additional file 2 of Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Author

Liu, Jun-Qi, Liao, Xi-Wen, Wang, Xiang-Kun, Cheng-Kun Yang, Zhou, Xin, Zheng-Qian Liu, Quan-Fa Han, Fu, Tian-Hao, Zhu, Guang-Zhi, Chuang-Ye Han, Su, Hao, Jian-Lu Huang, Guo-Tian Ruan, Yan, Ling, Ye, Xin-Ping, and Peng, Tao

Abstract

Additional file 2: Table 2. Basic characteristics of pancreatic ductal adenocarcinoma patients in The Cancer Genome Atlas database.

Published
2020
Full Text
View/download PDF

22. Additional file 3 of Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Author

Liu, Jun-Qi, Liao, Xi-Wen, Wang, Xiang-Kun, Cheng-Kun Yang, Zhou, Xin, Zheng-Qian Liu, Quan-Fa Han, Fu, Tian-Hao, Zhu, Guang-Zhi, Chuang-Ye Han, Su, Hao, Jian-Lu Huang, Guo-Tian Ruan, Yan, Ling, Ye, Xin-Ping, and Peng, Tao

Subjects
endocrine system diseases, digestive system diseases
Abstract

Additional file 3: Table 3. Basic characteristics of PDAC patients in Gene Expression Omnibus database.

Published
2020
Full Text
View/download PDF

23. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma

Author

Feng, Ji, primary, Lu, Pei-zhi, additional, Zhu, Guang-zhi, additional, Hooi, Shing Chung, additional, Wu, Yong, additional, Huang, Xiao-wei, additional, Dai, Hui-qi, additional, Chen, Pan-hong, additional, Li, Zhong-jie, additional, Su, Wen-jing, additional, Han, Chuang-ye, additional, Ye, Xin-ping, additional, Peng, Tao, additional, Zhou, Jing, additional, and Lu, Guo-dong, additional

Published
2020
Full Text
View/download PDF

24. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines

Author

Wang, Xiang‐Kun, primary, Liao, Xi‐Wen, additional, Yang, Cheng‐Kun, additional, Liu, Zheng‐Qian, additional, Han, Quan‐Fa, additional, Zhou, Xin, additional, Zhang, Lin‐Bo, additional, Deng, Teng, additional, Gong, Yi‐Zhen, additional, Huang, Jian‐Lu, additional, Huang, Rui, additional, Han, Chuang‐Ye, additional, Yu, Ting‐Dong, additional, Su, Hao, additional, Ye, Xin‐Ping, additional, Peng, Tao, additional, and Zhu, Guang‐Zhi, additional

Published
2020
Full Text
View/download PDF

25. Genome-wide RNA-sequencing dataset reveals the prognostic value and potential molecular mechanisms of lncRNA in non-homologous end joining pathway 1 in early stage Pancreatic Ductal Adenocarcinoma

Author

Shang, Li-Ming, primary, Liao, Xi-Wen, additional, Zhu, Guang-Zhi, additional, Huang, Ke-Tuan, additional, Han, Chuang-Ye, additional, Yang, Cheng-Kun, additional, Wang, Xiang-Kun, additional, Zhou, Xin, additional, Su, Hao, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2020
Full Text
View/download PDF

27. Novel candidate biomarkers of origin recognition complex 1, 5 and 6 for survival surveillance in patients with hepatocellular carcinoma

Author

Wang, Xiang-Kun, primary, Wang, Qiao-Qi, additional, Huang, Jian-Lu, additional, Zhang, Lin-Bo, additional, Zhou, Xin, additional, Liu, Jun-Qi, additional, Chen, Zi-Jun, additional, Liao, Xi-Wen, additional, Huang, Rui, additional, Yang, Cheng-Kun, additional, Zhu, Guang-Zhi, additional, Han, Chuang-Ye, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2020
Full Text
View/download PDF

28. Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy

Author

Zhu, Guang-Zhi, primary, Liao, Xi-Wen, additional, Wang, Xiang-Kun, additional, Gong, Yi-Zhen, additional, Liu, Xiao-Guang, additional, Yu, Long, additional, Han, Chuang-Ye, additional, Yang, Cheng-Kun, additional, Su, Hao, additional, Huang, Ke-Tuan, additional, Yu, Ting-Dong, additional, Huang, Jian-Lu, additional, Li, Jia, additional, Zeng, Zhi-Ming, additional, Qin, Wei, additional, Liu, Zheng-Qian, additional, Zhou, Xin, additional, Liu, Jun-Qi, additional, Lu, Lei, additional, Han, Quan-Fa, additional, Shang, Li-Ming, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2020
Full Text
View/download PDF

31. Diagnostic and prognostic biomarkers of Human Leukocyte Antigen complex for hepatitis B virus-related hepatocellular carcinoma

Author

Wang, Xiang-Kun, primary, Liao, Xi-Wen, additional, Yang, Cheng-Kun, additional, Yu, Ting-Dong, additional, Liu, Zheng-Qian, additional, Gong, Yi-Zhen, additional, Huang, Ke-Tuan, additional, Zeng, Xian-Min, additional, Han, Chuang-Ye, additional, Zhu, Guang-Zhi, additional, Qin, Wei, additional, and Peng, Tao, additional

Published
2019
Full Text
View/download PDF

32. Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma

Author

Yang, Cheng–kun, primary, Wang, Xiang–kun, additional, Liao, Xi–wen, additional, Han, Chuang–ye, additional, Yu, Ting–dong, additional, Qin, Wei, additional, Zhu, Guang–zhi, additional, Su, Hao, additional, Yu, Long, additional, Liu, Xiao–guang, additional, Lu, Si–cong, additional, Chen, Zhi–wei, additional, Liu, Zhen, additional, Huang, Ke–tuan, additional, Liu, Zheng–tao, additional, Liang, Yu, additional, Huang, Jian–lu, additional, Xiao, Kai–yin, additional, Peng, Min–hao, additional, Winkle, Cheryl Ann, additional, O'Brien, Stephen J., additional, and Peng, Tao, additional

Published
2017
Full Text
View/download PDF

33. Genome-Wide Association Study of MKI67 Expression and its Clinical Implications in HBV-Related Hepatocellular Carcinoma in Southern China

Author

Yang, Cheng-kun, primary, Yu, Ting-dong, additional, Han, Chuang-ye, additional, Qin, Wei, additional, Liao, Xi-wen, additional, Yu, Long, additional, Liu, Xiao-guang, additional, Zhu, Guang-zhi, additional, Su, Hao, additional, Lu, Si-cong, additional, Chen, Zhi-wei, additional, Liu, Zhen, additional, Huang, Ke-tuan, additional, Liu, Zheng-tao, additional, Liang, Yu, additional, Huang, Jian-lu, additional, Mo, Zeng-nan, additional, Qin, Xue, additional, Li, Lequn, additional, Xiao, Kai-yin, additional, Peng, Min-hao, additional, Winkle, Cheryl Ann, additional, O'Brien, Stephen J., additional, and Peng, Tao, additional

Published
2017
Full Text
View/download PDF

34. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27 kip1 Axis.

Author

Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, and Peng T

Abstract

Background: Cytochrome P450 2C8 (CYP2C8) gene is one of the members of the cytochrome P450 enzymes (CYPs) gene family. The aim of this study was to reveal the function of CYP2C8 in hepatocellular carcinoma (HCC) and its effect on the sorafenib resistance., Methods: Differential expression analysis in multiple HCC datasets all suggested that CYP2C8 expression was significantly decreased in HCC tissues, compared with para-carcinoma liver tissues. The expression level of CYP2C8 was subsequently compared between HCC tissues and para-carcinoma liver tissues of 70 patients form Guangxi, China, with the result consistent with the above. Survival analysis and ROC analysis indicated that CYP2C8 was equipped with satisfactory diagnostic and prognostic value in HCC. To examine the effect of CYP2C8 on the malignant phenotype of HCC cells, stable transcriptional cell lines with CYP2C8 over-expression were established, and then Cell Counting Kit-8 (CCK8) assay, colony formation assay, cell cycle assay, cell invasion assay and wound healing assay were performed., Results: The results of aforementioned assays suggested that CYP2C8 over-expression restricted the proliferation, clonality, migration, invasion and cell cycle of HCC cells but had no significant effect on cell apoptosis. The enrichment analysis in terms of sequencing data of HCC cell lines with stable CYP2C8 over-expression suggested that CYP2C8 might be related to PI3K/Akt/p27 Kip1 axis. The inhibition of CYP2C8 over-expression on PI3K/Akt/p27 Kip1 axis was subsequently demonstrated with Western blot assay. In the rescue experiment, it was observed that both P27 inhibitor and PI3K agonist counteracted the repressed malignant phenotype caused by CYP2C8 over-expression, which further demonstrated that CYP2C8 played a role in HCC cells via PI3K/Akt/p27 Kip1 axis., Discussion: The results demonstrated that CYP2C8 enhances the anticancer activity of sorafenib in vitro assays and in tumor xenograft model, with Ki-67 down-regulation and PI3K/Akt/p27Kip1 axis inhibition. In conclusion, these findings hinted that CYP2C8 restricted malignant phenotype and sorafenib resistance in HCC via PI3K/Akt/p27 kip1 axis., Competing Interests: The authors declared that they have no competing interests., (© 2021 Zhou et al.)

Published
2021
Full Text
View/download PDF

35. Oncogene UBE2I enhances cellular invasion, migration and proliferation abilities via autophagy-related pathway resulting in poor prognosis in hepatocellular carcinoma.

Author

Wang XK, Liao XW, Zhou X, Han CY, Chen ZJ, Yang CK, Huang JL, Wang JY, Liu JQ, Huang HS, Mo ST, Ye XP, Zhu GZ, and Peng T

Abstract

Hepatocellular carcinoma (HCC) is a worldwide malignancy with high morbidity and mortality. In this study, ubiquitin conjugating enzyme E2I ( UBE2I ), a small ubiquitin-like modifier E2 enzyme reportedly expressed in tumors, was examined for its potential effects in HCC. Bioinformatics analysis was performed based on HCCDB, TIMER, and Kaplan-Meier plotter databases to explore the clinical implications in HCC. An siRNA kit was used to downregulate UBE2I, and in vitro experiments-including migration, invasion and proliferation assays-were performed to examine UBE2I expression in HCC. Western blot (WB) was used to determine whether downregulated UBE2I expression influenced the prognosis of HCC via autophagy pathways. Finally, RNA-sequencing was performed to explore candidate molecular mechanisms underlying the effect of UBE2I. Bioinformatics analysis including stratification by alcohol ingestion and hepatitis status in HCC showed that highly expressed UBE2I was not only correlated with poor prognosis, but was also associated with immune infiltrates. In vitro experiments showed that high expression of UBE2I was associated with increased migration, invasion and proliferation of HCC cells. WB results indicated that downregulated expression of UBE2I was associated with higher levels of autophagy-related proteins including LC3A/B, Beclin-1 and ATG16L1. Moreover, RNA-sequencing results suggested that UBE2I was involved in hepatocarcinogenesis, non-alcohol fatty liver disease, steatohepatitis, liver fibrosis, inflammation, hepatoblastoma, tumor angiogenesis, type 2 mellitus diabetes, biliary tract disease and other diseases. We conclude that oncogene UBE2I is associated with poor prognosis of HCC via autophagy pathways and may be involved in hepatocarcinogenesis, tumor angiogenesis, non-alcohol fatty liver disease and inflammation., Competing Interests: None., (AJCR Copyright © 2020.)

Published
2020

36. Distinct effects of anti-diabetic medications on liver cancer risk and patient survival.

Author

Chen PH, Zhu GZ, Li L, Chen Y, Dai HQ, Su WJ, Wu Y, and Zhou J

Subjects
Female, Humans, Liver Neoplasms mortality, Male, Metformin pharmacology, Risk Factors, Survival Analysis, Diabetes Mellitus, Type 2 drug therapy, Liver Neoplasms drug therapy, Metformin therapeutic use
Abstract

Type 2 diabetes mellitus (T2DM) is a pandemic metabolic disease worldwide. Multiple types of cancer, particularly liver cancer, are closely associated with T2DM. As a result, there is growing interest in investigating whether anti-diabetic medications could lower cancer risks in the population and even prolong patient survival among those with concurrent cancer. There are many types of anti-diabetic medications available in the clinic. The present study reviewed how different anti-diabetic drugs affect cancer risk and patient survival. On the one hand, multiple retrospective studies have shown that the different anti-diabetic medications have distinct effects on cancer risks. Insulin-raising drugs, including exogenous insulin, increased cancer risks, while drugs potentiating insulin sensitivity like metformin reduced cancer risks. On the other hand, the effects of anti-diabetic medications on patient survival are relatively less studied, except limited reports in liver cancer and pancreatic cancer. It seems that metformin could extend overall survival in patients of early-stage cancer. In contrast in the advanced cancer with metastasis, metformin has no effect or even worsens cancer mortality. It is yet unknown whether these distinct effects of metformin are attributable to the severity of the cancer staging or to the drug interactions between metformin and other medications. This question warrants reconsideration of the current clinical practice in the control of T2DM. Future large-scale prospective studies are needed to resolve this.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results